Is Life-Sciences Real Estate Outside the Golden Triangle Investable?

Yes, life-sciences real estate outside the Golden Triangle can be investable, but only in locations where universities, teaching hospitals, research institutions, skilled labour and funded occupiers create durable demand. In MCG’s assessment, Manchester has one of the broadest regional propositions, while Birmingham, Leeds, Liverpool, Sheffield and Nottingham offer more selective opportunities. Entry costs and development and leasing risks vary materially by asset and submarket.

TL;DR

• A successful regional life-sciences cluster needs research institutions, clinical infrastructure, talent, capital and suitable property—not merely laboratory branding.
• In MCG’s assessment, Manchester is among the most mature large-scale propositions outside London, Oxford and Cambridge, although individual schemes still require rigorous demand testing.
• Birmingham, Leeds, Liverpool, Sheffield and Nottingham offer credible specialist clusters, but their occupier pools are generally narrower.
• Laboratory conversion is technically demanding: power, ventilation, structure, servicing, resilience and planning can materially alter returns.
• Investors should underwrite realistic local rents and absorption rather than assume Golden Triangle economics will transfer to regional cities.

What counts as life-sciences real estate?

Life-sciences real estate comprises buildings used for scientific research, testing, diagnostics, healthcare innovation and the manufacture or commercialisation of related products. It can include wet laboratories, dry laboratories, research and development offices, clean rooms, incubators, clinical facilities and specialist manufacturing space.

It is not a single property type. A computational biology occupier may need office-like space with strong digital infrastructure, while a biotechnology company conducting wet-lab research may require high air-change rates, specialist drainage, backup power, gas storage and tightly controlled environments. Advanced manufacturing and Good Manufacturing Practice facilities introduce a different specification and regulatory burden again.

This distinction matters because the investment case depends on the building’s genuine fitness for identified occupiers. A conventional office fitted with laboratory benches is not necessarily institutional-grade scientific accommodation.

Life-sciences property types at a glance

| Property type | Typical occupiers | Core requirements | Principal investment risk | |—|—|—|—| | Wet laboratory | Biotechnology, diagnostics and pharmaceutical research | Ventilation, drainage, power, gases and resilient services | High fit-out cost and limited alternative use | | Dry laboratory | Data science, medical technology and computational research | Digital connectivity, power and flexible workspace | Competition from conventional offices | | Incubator space | University spin-outs and early-stage companies | Small flexible units, shared equipment and short-form occupation | Tenant churn and management intensity | | Clinical research facility | Hospitals, contract research organisations and diagnostics groups | Patient access, compliance and clinical adjacency | Planning, regulation and specialised demand | | Specialist manufacturing | Advanced therapy, diagnostics and pharmaceutical producers | Clean rooms, logistics, utilities and process infrastructure | Capital intensity and occupier-specific specification | | R&D office hybrid | Established science and healthcare companies | Office space combined with adaptable technical areas | Risk that premium rents exceed functional value |

Why investors look beyond the Golden Triangle

The Golden Triangle—London, Oxford and Cambridge—contains the UK’s deepest concentration of universities, research institutions, venture capital and life-sciences companies. Its strengths are substantial, but so are land values, construction costs, competition and barriers to expansion.

Regional cities can offer lower occupational costs, larger development sites and access to universities and NHS teaching hospitals. For companies moving from grant-funded research to trials, diagnostics or production, proximity to clinical networks and affordable technical labour may be as important as proximity to venture capital.

Government policy also supports a broader national innovation economy. The UK’s life-sciences strategy, university research funding, regional innovation programmes and the work of entities such as UK Research and Innovation can help clusters develop. However, policy designation does not by itself produce lease demand.

For family offices, GCC investors and institutional capital, the potential attraction is a combination of specialist income, lower land basis and exposure to healthcare and scientific innovation. The trade-off is weaker rental evidence, less liquidity and a smaller pool of replacement occupiers than in the strongest Golden Triangle locations.

> Golden Triangle vs regional clusters > > – Occupier depth: The Golden Triangle generally has the larger pool; regional markets often depend on a few institutions or specialist sectors. > – Entry basis: Regional land and existing buildings can be less expensive; technical construction costs remain substantial everywhere. > – Rental evidence: Prime clusters provide more comparables; regional laboratory rents can be difficult to verify. > – Exit liquidity: London, Oxford and Cambridge usually attract a broader institutional buyer base; regional exits are more sensitive to lease quality and covenant strength. > – Expansion capacity: Regional cities can offer larger sites and lower-cost pathways from research to manufacturing.

Which regional cities have the strongest propositions?

There is no single league table that captures investability. Investors should examine each city’s scientific specialisms, anchor institutions, existing occupiers, available laboratories and development pipeline.

| City | Principal strengths | Important anchors and districts | Main underwriting issue | |—|—|—|—| | Manchester | Broad research base, major clinical infrastructure and established innovation districts | University of Manchester, Manchester University NHS Foundation Trust, Manchester Science Park, Citylabs and Alderley Park in the wider region | Whether supply and rents match proven occupier depth at each submarket | | Birmingham | Large healthcare ecosystem, university research and central connectivity | University of Birmingham, Queen Elizabeth Hospital Birmingham and Birmingham Health Innovation Campus | Translating research strength into sustained private-sector take-up | | Leeds | Strong health-data, medical technology and NHS links | University of Leeds, Leeds Teaching Hospitals NHS Trust and the wider innovation district | Limited evidence for large speculative laboratory schemes | | Liverpool | Infectious disease, public health, materials science and established science infrastructure | University of Liverpool, Liverpool School of Tropical Medicine, Knowledge Quarter Liverpool and Liverpool Science Park | Smaller occupier pool and concentration risk | | Sheffield | Advanced manufacturing, health technology and university research | University of Sheffield, Sheffield Teaching Hospitals and the Advanced Manufacturing Research Centre | Demand may span laboratories, manufacturing and hybrid space rather than a conventional lab model | | Nottingham | Pharmaceuticals heritage, bioscience research and university-linked innovation | University of Nottingham, Nottingham Trent University and BioCity Nottingham | Scale, follow-on space and the depth of larger private occupiers |

Manchester

In MCG’s assessment, Manchester presents one of the broadest regional ecosystems. The University of Manchester, NHS infrastructure and established locations such as Manchester Science Park and Citylabs create a combination of research, clinical access and commercial accommodation. Alderley Park adds a major science campus within the wider North West cluster.

The city is nevertheless not a single uniform market. Oxford Road Corridor, city-centre locations and out-of-town campuses serve different occupiers. Investors must test how many organisations genuinely need the proposed location and specification rather than treating city-wide research activity as immediate demand.

Birmingham and Leeds

Birmingham benefits from a major university, Queen Elizabeth Hospital Birmingham and a large regional population. Its opportunity is closely tied to healthcare innovation, diagnostics and translation from research into commercial use. The challenge is demonstrating sufficient recurring demand beyond anchor-led schemes.

Leeds has a credible proposition in health technology, data and medical innovation, supported by the University of Leeds and Leeds Teaching Hospitals NHS Trust. Some occupiers may need hybrid office, digital and clinical space rather than heavily serviced wet laboratories, so product design should follow demand.

Liverpool, Sheffield and Nottingham

Liverpool’s strengths include infectious disease, tropical medicine, public health and materials science. The Knowledge Quarter and established science facilities provide a foundation, but smaller markets are vulnerable to tenant concentration and irregular leasing velocity.

Sheffield combines clinical research with advanced manufacturing and engineering. This can support laboratories, prototyping facilities and technical production space, although it does not necessarily justify a generic urban laboratory scheme.

Nottingham has a recognised bioscience base and pharmaceutical heritage, including BioCity Nottingham. The core questions are whether early-stage companies can scale locally and whether the market provides suitable follow-on accommodation as occupiers mature.

How should investors test a regional cluster?

A cluster should be assessed through evidence of commercial activity, not the number of nearby academic papers or promotional announcements. The following checklist is suitable for acquisitions, developments and conversions.

Seven-point investment checklist

1. Map the anchors. Identify universities, teaching hospitals, research institutes, established companies and science parks within a practical travel area.
2. Audit occupier demand. Verify active requirements, recent lettings, lease expiries, company funding stages and the size of the realistic tenant pool.
3. Separate wet and dry demand. Establish whether occupiers need true wet laboratories, office-led R&D, clinical space or advanced manufacturing.
4. Review competing supply. Include fitted laboratories, planned developments, incubators and space retained within universities or hospitals.
5. Test rental affordability. Compare rent plus service charge, utilities and fit-out obligations with occupiers’ funding and alternatives.
6. Assess expansion pathways. Determine whether companies can move from incubator space into larger laboratories or production facilities without leaving the cluster.
7. Plan the exit before entry. Model buyers’ likely treatment of covenant, lease length, technical obsolescence, reletting expenditure and alternative use.

Demand evidence should include conversations with occupiers and leasing agents, corporate filings, funding announcements and actual property transactions. Market reports from JLL, CBRE, Savills, Knight Frank and Colliers can provide useful context, but national demand figures should not be applied mechanically to a particular city.

Building specification, conversion and development risk

Laboratories place greater demands on a building than conventional offices. Ceiling heights, slab loading, risers, vibration control, goods access, hazardous-material handling and plant capacity can all determine whether a property is viable. A conversion that appears inexpensive before technical due diligence may require major structural and mechanical intervention.

Power is especially important. Scientific equipment, air handling, cooling and resilient systems can create substantial loads. Grid constraints and long connection times can delay delivery. Investors should also model energy consumption and service charges because an efficient building can still be expensive to operate when laboratory equipment and ventilation run continuously.

Planning and regulatory treatment depend on the proposed activities and location. Investors should use specialist planning, environmental, fire, mechanical and electrical, and laboratory consultants. Relevant requirements may include building regulations, health and safety obligations, environmental permits, waste handling and controls for biological or chemical materials.

Technical due-diligence priorities

• Confirm available electrical capacity, connection timing and backup requirements.
• Test floor loading, vibration criteria, floor-to-ceiling heights and plant zones.
• Review ventilation, extract routes, air changes and heat-recovery options.
• Check water, drainage, gases, effluent treatment and hazardous-waste logistics.
• Analyse loading access, goods lifts, deliveries and separation of public and technical circulation.
• Cost the reinstatement and reconfiguration required for a replacement tenant.
• Evaluate office or alternative-use value if specialist demand weakens.

Speculative fitted laboratories can shorten occupation times for early-stage companies, but they expose the owner to equipment selection and obsolescence risk. Shell laboratory-ready space reduces upfront expenditure but may be unaffordable for smaller occupiers unless landlords contribute significant capital.

Capital structure, income and exit strategy

Life-sciences real estate should not automatically be valued as a bond-like alternative asset. Income security depends on the tenant’s covenant, funding runway, lease structure and the building’s reletting prospects. A venture-backed biotechnology company may occupy technically sophisticated space while retaining a comparatively short financial runway.

A robust underwriting model should distinguish three layers of capital expenditure:

1. Base building and infrastructure.
2. Laboratory fit-out and shared equipment.
3. Occupier-specific works and subsequent reinstatement.

The model should then allocate ownership and residual value for each layer. Rent-free periods, landlord contributions and phased occupation can be significant. Service-charge recovery also requires scrutiny because smaller science companies may resist the full operating cost of complex common systems.

Typical risks by strategy

| Strategy | Potential advantage | Principal risk | Appropriate mitigation | |—|—|—|—| | Stabilised acquisition | Existing income and operating evidence | Overpaying for a specialist lease with weak covenant | Review tenant cash runway, lease events and replacement demand | | Office-to-lab conversion | Lower initial building basis | Hidden structural and servicing costs | Complete intrusive technical and power due diligence before acquisition | | Ground-up development | Purpose-designed product | Long delivery period and uncertain absorption | Phase delivery and secure anchor commitments where possible | | Incubator platform | Access to growing companies | Short occupation, intensive management and tenant failures | Diversify occupiers and provide controlled expansion space | | Sale-and-leaseback | Long lease may support income | Facility can be highly occupier-specific | Assess covenant independently and model alternative use |

Debt availability will depend on pre-letting, sponsor experience, covenant and alternative-use value. The Bank of England base rate affects development finance and exit pricing, but specialist execution risk can matter more than small movements in the risk-free rate. Regulated financial advice should come from an FCA-authorised adviser where relevant.

Tax structuring also requires professional advice. A Ltd company acquisition, joint venture or offshore structure can produce different outcomes for corporation tax, withholding, financing and governance. Non-residential and mixed-use acquisitions are subject to their applicable Stamp Duty Land Tax rules in England; investors should confirm treatment through gov.uk guidance and qualified tax counsel rather than assume the residential SDLT surcharge applies in the same way.

McGardens’ view

McGardens Estate (MCG) is a UK real estate investment and management firm advising family offices, GCC and overseas private capital and institutional investors, and managing UK rental portfolios for overseas landlords.

MCG’s assessment is that regional life-sciences property is investable as a cluster-specific operational strategy, not as a generic thematic allocation. Manchester offers the strongest combination of scale, anchors and established infrastructure outside the Golden Triangle, but even there a credible city narrative cannot substitute for verified demand at the building level.

The most compelling regional opportunities are likely to have at least one of three characteristics: an anchor-backed innovation district; a fitted asset with observable leasing evidence; or a facility serving a defined specialism such as diagnostics, infectious disease, medical technology or advanced manufacturing. Generic speculative laboratories in secondary office locations carry a materially weaker risk profile.

For family offices and GCC investors, a patient-capital approach may suit phased campuses and partnership structures, particularly where land can support expansion. Institutional investors are more likely to require demonstrable income, professional operations and clear exit liquidity. In both cases, management capability matters because occupier engagement, shared services and technical maintenance are integral to performance.

MCG would favour underwriting based on downside rents, longer absorption periods and explicit reletting capital. Any upside from cluster maturation should be treated as optionality rather than embedded in the acquisition price.

Key takeaways

• Regional life-sciences real estate is a collection of local markets, not one national asset class.
• MCG considers Manchester to offer a broad regional proposition, while Birmingham, Leeds, Liverpool, Sheffield and Nottingham provide specialist opportunities.
• Universities and hospitals are necessary anchors but do not guarantee commercial take-up.
• Building engineering, power and fit-out can determine returns more decisively than headline rent.
• Covenant, funding runway and replacement demand should be assessed together.
• Investors should preserve alternative use and avoid pricing unproven regional demand as established Golden Triangle demand.

FAQ

What is the UK’s life-sciences Golden Triangle?

The UK’s life-sciences Golden Triangle is the research and commercial cluster formed by London, Oxford and Cambridge. It contains leading universities, hospitals, research institutes, venture capital and biotechnology and pharmaceutical companies. The term describes an economic geography rather than a legal boundary, and its concentration of capital and occupiers generally supports deeper property demand than most regional markets.

Is Manchester a mature life-sciences property market?

MCG considers Manchester one of the UK’s broadest major regional life-sciences propositions, supported by the University of Manchester, significant NHS infrastructure, Manchester Science Park, Citylabs and the wider North West ecosystem. It is not uniformly mature across every submarket or laboratory type, however. Investors still need evidence of live requirements, achieved rents, competing supply and replacement demand for each asset.

Which UK cities outside the Golden Triangle are best for life-sciences investment?

Manchester, Birmingham, Leeds, Liverpool, Sheffield and Nottingham each have credible strengths, but no city is best for every strategy. Manchester offers scale; Birmingham and Leeds have strong clinical and health-innovation links; Liverpool has infectious-disease expertise; Sheffield combines research with advanced manufacturing; and Nottingham has bioscience and pharmaceutical heritage. Asset-level demand remains decisive.

Can an office building be converted into laboratories?

An office building can be converted into laboratories only if its structure, power, ventilation, servicing and access are suitable or economically upgradeable. Wet laboratories may require additional plant, extract routes, drainage, gases and resilience that conventional offices lack. Intrusive technical due diligence, planning review and a fully costed specification should precede acquisition because superficial conversion budgets can materially understate expenditure.

Are life-sciences leases safer than conventional office leases?

Life-sciences leases are not inherently safer than conventional office leases. Specialist fit-out can make occupiers reluctant to move, but many early-stage companies have limited revenue and depend on external funding. Investors should assess covenant strength, cash runway, lease terms, landlord capital, reinstatement costs and the size of the replacement-tenant pool rather than relying on the sector label.

How should overseas investors access regional life-sciences real estate?

Overseas investors should use a locally governed structure with specialist property, technical, tax and legal advisers. Suitable routes may include direct acquisitions, joint ventures with experienced developers, stabilised assets or phased campus investments. Family offices and GCC investors should match development and leasing risk to their return target and obtain advice on UK tax, financing, regulation and operational oversight.